| Literature DB >> 30857243 |
Marta Sofía Valero1,2, Mariano Ramón-Gimenez3, Javier Lozano-Gerona4,5, Pablo Delgado-Wicke6, Pilar Calmarza7, Aida Oliván-Viguera8,9, Víctor López10,11, Ángel-Luis Garcia-Otín12,13, Salvador Valero14, Esther Pueyo15,16, Kirk L Hamilton17, Hiroto Miura18, Ralf Köhler19,20,21.
Abstract
Abstract: The epithelial intermediate-conductance calcium/calmodulin-regulated KCa3.1 channel is considered to be a regulator of intestine function by controlling chloride secretion and water/salt balance. Yet, little is known about the functional importance of KCa3.1 in the intestinal epithelium in vivo. Our objective was to determine the impact of epithelial-specific inducible overexpression of a KCa3.1 transgene (KCa3.1+) and of inducible suppression (KCa3.1-) on intestinal homeostasis and function in mice. KCa3.1 overexpression in the duodenal epithelium of doxycycline (DOX)-treated KCa3.1+ mice was 40-fold above the control levels. Overexpression caused an inflated duodenum and doubling of the chyme content. Histology showed conserved architecture of crypts, villi, and smooth muscle. Unaltered proliferating cell nuclear antigen (PCNA) immune reactivity and reduced amounts of terminal deoxynucleotide transferase mediated X-dUTP nick end labeling (TUNEL)-positive apoptotic cells in villi indicated lower epithelial turnover. Myography showed a reduction in the frequency of spontaneous propulsive muscle contractions with no change in amplitude. The amount of stool in the colon was increased and the frequency of colonic contractions was reduced in KCa3.1+ animals. Senicapoc treatment prevented the phenotype. Suppression of KCa3.1 in DOX-treated KCa3.1- mice caused no overt intestinal phenotype. In conclusion, inducible KCa3.1 overexpression alters intestinal functions by increasing the chyme content and reducing spontaneous contractions and epithelial apoptosis. Induction of epithelial KCa3.1 can play a mechanistic role in the process of adaptation of the intestine.Entities:
Keywords: KCa3.1; contractility; duodenum; epithelium; intermediate-conductance calcium-activated potassium channel; transgenic mice
Mesh:
Substances:
Year: 2019 PMID: 30857243 PMCID: PMC6429421 DOI: 10.3390/ijms20051193
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1KCa3.1 overexpression in inducible KCa3.1+ mice. Induction of KCa3.1 transgene expression by 2-weeks in doxycycline (DOX)-treated KCa3.1+ mice (+DOX) and untreated KCa3.1+ (−DOX) in (A) the duodenum and (B) duodenal epithelium measured by qRT-PCR. Expression was normalized to GAPDH expression (% GAPDH). (C) The ratio (epithelium/duodenum) of induction of transgene expression. (D) Gel electrophoresis showing qRT-PCR. Note the more intense bands in the DOX-treated mice. GAPDH, Glyceraldehyde-3-Phosphate Dehydrogenase; − DOX, untreated KCa3.1+ mice; + DOX, DOX-treated KCa3.1+ mice. The data are means ± SEM, n = 2–14 (mice).
Changes in water and food consumption and amounts and water content of stools. − DOX, untreated KCa3.1+ mice. + DOX, doxycycline-treated KCa3.1+ mice.
| −DOX | +DOX | ||||
|---|---|---|---|---|---|
| Mean + SEM | Mean + SEM | ||||
| Water intake 1st week (mL/day) | 4.7 ± 0.3 | 33 | 4.1 ± 0.4 | 34 | ns |
| Water intake 2nd week (mL/day) | 4.2 ± 0.3 | 33 | 6.8 ± 0.6 | 34 | 0.0005 |
| Food intake (g) | 1.4 ± 0.2 | 11 | 1.7 ± 0.2 | 9 | ns |
| Wet weight (mg) | 97 ± 10 | 11 | 140 ± 11 | 14 | 0.009 |
| Dry weight (mg) | 27 ± 3 | 11 | 40 ± 3 | 14 | 0.009 |
| Water content (%) | 72 ± 1 | 11 | 71 ± 1 | 14 | ns |
ns: not significant.
Effects of overexpression of KCa3.1 on the weight of the gastrointestinal package, small intestine, stomach, caecum, and colon. Organ weights were normalized to body weight and expressed as a percentage of body weight ((g organ/g BW)×100). − DOX, untreated KCa3.1+ mice. + DOX, doxycycline-treated KCa3.1+ mice.
| − DOX | + DOX | ||||
|---|---|---|---|---|---|
| Mean ± SEM | Mean ± SEM | ||||
| GI package | 12.7 ± 0.6 | 12 | 17.5 ± 1.8 | 8 | 0.0328 |
| Small intestine | 6.5 ± 0.4 | 12 | 10.4 ± 1.2 | 8 | 0.0120 |
| Stomach | 1.7 ± 0.2 | 10 | 2.1 ± 0.3 | 8 | ns |
| Caecum | 1.6 ± 0.1 | 12 | 4.9 ± 0.6 | 8 | <0.0001 |
| Colon | 1.6 ± 0.2 | 12 | 1.5 ± 0.1 | 8 | ns |
GI: gastrointestinal, BW: body weight.
Figure 2Intestinal content and morphology of the duodenum in DOX-treated (+ DOX) and untreated KCa3.1+ mice (− DOX). (A) Small intestine weight. (B) Chyme content. (C) Hematoxylin–eosin-stained cross-section of the duodenum of the untreated and DOX-treated KCa3.1+ mice, duodenal lumen area and thickness of the longitudinal and circular smooth muscle layers. The data are means ± SEM.; n = 6–15 (mice). * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 3Electrolytic content of stool, chyme, and plasma. Na+, K+, and Cl− concentrations in (A) dried stools, (B) chyme, and (C) serum of untreated (− DOX) and DOX-treated KCa3.1+ mice (+ DOX). The data are mean ± SEM, n = 3–8 (mice).
Figure 4Immune histological examination of proliferating cell nuclear antigen (PCNA) protein expression and terminal deoxynucleotide transferase mediated X-dUTP nick end labeling (TUNEL) in KCa3.1+ mice. (A) PCNA-stained and hematoxylin–eosin-counterstained epithelium of untreated (− DOX) and DOX-treated (+ DOX) mice and qualitative scores of intensity. (B) Apoptosis in treated and untreated KCa3.1+ mice determined by TUNEL, qualitative scores (panel on right), and quantitative evaluation (lower panels) of signal intensity (% TUNEL-positive; on left) normalized to epithelial area and total 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI)-positive area (pixel (px); on right). The data are means ± SEM., n = 5 (mice). * p < 0.05.
Figure 5Impact of KCa3.1 transgene induction on duodenal contractility. (A) Recording of spontaneous contractions from the longitudinal smooth muscle of untreated (− DOX) and DOX-treated KCa3.1+ mice (+ DOX). (B) Frequency and (C) amplitude of spontaneous contractions. (D) Contractile response to acetylcholine (ACh, at 100 µM). The data are means (% of − DOX) ± SEM. (E) There was no impact of TRAM-34 (1 µM) on the frequency and amplitude of the contractions. The data are means (% of – TRAM-34 (before addition TRAM-34) ± SEM.; n = 12–16 (mice). ** p < 0.01.
Figure 6Impact of KCa3.1 induction on colon contractility. (A) Recordings of spontaneous contractions in the colonic longitudinal smooth muscle segments of the untreated (− DOX) and DOX-treated KCa3.1+ mice (+ DOX). (B) Frequency and (C) amplitude of the spontaneous contractions. (D) Contractions to acetylcholine (ACh, at 100 µM). The data are given as % of untreated KCa3.1+ mice (− DOX) ± SEM. (E) There was no impact of TRAM-34 (1 µM) on the frequency and amplitude of the contractions. The data are means (% of – TRAM-34 (before addition TRAM-34) ± SEM.; n = 12–16 (mice). * p < 0.05.
In vivo Senicapoc treatment prevents the intestinal phenotype in DOX-treated KCa3.1+ mice. The data are expressed as % of untreated KCa3.1+ mice (− DOX) ± SEM.
| + DOX | |||
|---|---|---|---|
| (% of –DOX) | |||
| Water intake 1st week | 79 ± 27 | 4 | ns |
| Water intake 2nd week | 98 ± 17 | 5 | ns |
| Food intake | 147 ± 22 | 5 | ns |
| GI package | 121 ± 9 | 6 | ns |
| Small intestine | 123 ± 17 | 6 | ns |
| Stomach | 120 ± 17 | 6 | ns |
| Caecum | 125 ± 12 | 6 | ns |
| Colon | 100 ± 20 | 6 | ns |
| Chyme | 74 ± 9 | 6 | ns |
| ILA | 105 ± 30 | 6 | ns |
| Frequency | 102 ± 23 | 6 | ns |
| Amplitude | 90 ± 13 | 6 | ns |
| Frequency | 96 ± 4 | 6 | ns |
| Amplitude | 105 ± 3 | 6 | ns |
GI: gastrointestinal, ILA: small intestine lumen area, ns: not significant.
Figure 7Gene targeting strategy and generation of epithelium-specific inducible KCa3.1− mice.
Suppression of KCa3.1 in KCa3.1− mice causes no overt intestinal phenotype. Organ weights were normalized to body weight (BW) and expressed as a percentage of BW ((g organ/g BW) × 100). The intestinal contractility data are given as % of control (untreated KCa3.1− mice (− DOX)).
| − DOX | + DOX | ||||
|---|---|---|---|---|---|
| Mean ± SEM | Mean ± SEM | ||||
| Water intake 1st week (mL/d) | 1.8 ± 0.1 | 9 | 1.9 ± 1.0 | 12 | ns |
| Wet weight (mg) | 236 ± 31 | 9 | 213 ± 29 | 15 | ns |
| Dry weight (mg) | 40.7 ± 6.3 | 9 | 36.0 ± 5.2 | 15 | ns |
| Water content (%) | 81.3 ± 0.5 | 9 | 81.5 ± 1.3 | 15 | ns |
| GI package | 19.8 ± 1.0 | 9 | 21.8 ± 0.3 | 15 | ns |
| Small intestine | 6.3 ± 0.3 | 9 | 7.2 ± 0.4 | 15 | ns |
| Stomach | 1.8 ± 0.1 | 9 | 2.1 ± 0.1 | 15 | ns |
| Caecum | 2.6 ± 0.1 | 9 | 3.1 ± 0.2 | 15 | ns |
| Colon | 1.9 ± 0.1 | 9 | 2.0 ± 0.1 | 15 | ns |
| Chyme (mL) | 0.3 ± 0.0 | 9 | 0.4 ± 0.0 | 15 | ns |
| ILA (mm2) | 0.1 ± 0.0 | 9 | 0.2 ± 0.0 | 15 | ns |
| Frequency (% of − DOX) | 100 ± 2 | 8 | 99 ± 2 | 8 | ns |
| Amplitude (% of − DOX) | 100 ± 16 | 8 | 99 ± 13 | 8 | ns |
| Frequency (% change-TRAM-34) | 103 ± 1 | 8 | 100 ± 3 | 8 | ns |
| Amplitude (% change-TRAM-34) | 99 ± 18 | 8 | 98 ± 24 | 8 | ns |
| Frequency (% of − DOX) | 100 ± 6 | 8 | 116 ± 7 | 8 | ns |
| Amplitude (% of − DOX) | 100 ± 17 | 8 | 96 ± 19 | 8 | ns |
| Frequency (% change-TRAM-34) | 99 ± 4 | 8 | 98 ± 4 | 8 | ns |
| Amplitude (% change-TRAM-34) | 105 ± 20 | 8 | 96 ± 12 | 8 | ns |
d: day. GI, gastrointestinal. ILA: Small intestine lumen area. ns: not significant.
Figure 8Immune histological examination of PCNA protein expression and TUNEL in KCa3.1− mice. (A) PCNA-stained and hematoxylin–eosin-counterstained epithelium of the untreated (− DOX) and DOX-treated KCa3.1− (+ DOX) mice and qualitative scores of intensity. (B) Apoptosis in the treated and untreated KCa3.1− mice determined by TUNEL, qualitative scores (panel on right), and quantitative evaluation (lower panels of signal intensity (% TUNEL-positive; on left) normalized to epithelial area and total DAPI-positive area (pixel (px); on right)). The data are means ± SEM., n = 4 (mice).